Vaxart, Inc.

Last price update: 02 Oct 24 23:00 GMT

Price:
$0.86
Open:
$0.82
Previous close:
$0.82
Day's range:
$0.80 - $0.88
Year's range:
$0.52 - $1.54
Net Income per Share:
-0.45
Price-to-Earnings ratio:
-1.92
52-week Price Range:
$0.79
Volume:
$1,004,071.00
Average volume:
$2,113,430.00

Company profile for Vaxart, Inc.

Vaxart, Inc. logo

Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.

Stock exchanges:
NASDAQ
Sector:
Healthcare
Industries:
Biotechnology
Ticker:
VXRT
CIK:
0000072444
ISIN:
US92243A2006
Website:
https://vaxart.com
Phone:
650 550 3500
Origin:
United States
Employees:
110

Vaxart, Inc. News

Vaxart to Present at World Vaccine & Immunotherapy Congress West Coast 2022 on November 29

Vaxart to Present at World Vaccine & Immunotherapy Congress West Coast 2022 on November 29

GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, will present at the World Vaccine & Immunotherapy Congress West Coast 2022 in San Diego on Tuesday, November 29, 2022 at 1:50 p.m. PT / 4:50 p.m. ET.

Vaxart, Inc. (VXRT) Q3 2022 Earnings Call Transcript

Vaxart, Inc. (VXRT) Q3 2022 Earnings Call Transcript

Seeking Alpha

Vaxart, Inc. (NASDAQ:VXRT ) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Brant Biehn - SVP, Business Operations Cezar Floroiu - CEO, President & Director Sean Tucker - SVP & Chief Scientific Officer James Cummings - Chief Medical Officer Conference Call Participants Pete Stavropoulos - Cantor Fitzgerald Sahil Kazmi - B. Riley Securities FBR Operator Greetings, and welcome to the Vaxart's Third Quarter 2022 Business Update and Financial Results Conference Call.

Vaxart to Present at World Vaccine Congress Europe 2022 on October 13

Vaxart to Present at World Vaccine Congress Europe 2022 on October 13

GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James Cummings, Chief Medical Officer, will make separate presentations at the World Vaccine Congress Europe 2022 in Barcelona, Spain on Thursday, October 13, 2022.

Vaxart to Host Conference Call on September 1 at 8:30 AM ET to Discuss Top-line Results from Its Phase II COVID-19 Trial

Vaxart to Host Conference Call on September 1 at 8:30 AM ET to Discuss Top-line Results from Its Phase II COVID-19 Trial

GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced it will release top-line data from the first part of its planned two-part COVID-19 Phase II trial of its Wuhan S-only construct before the market open on Thursday, September 1, 2022. The Vaxart senior management team will host a live conference call and webcast beginning at 8:30 a.m. Eastern Time on the same date to review the data and provide a trial update.

Vaxart, Inc. (VXRT) CEO Cezar Floroiu on Q2 2022 Results - Earnings Call Transcript

Vaxart, Inc. (VXRT) CEO Cezar Floroiu on Q2 2022 Results - Earnings Call Transcript

Seeking Alpha

Vaxart, Inc. (NASDAQ:VXRT ) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Brant Biehn - SVP, Business Operations Cezar Floroiu - CEO, President & Director Sean Tucker - SVP & Chief Scientific Officer James Cummings - Chief Medical Officer Conference Call Participants Pete Stavropoulos - Cantor Fitzgerald Kumaraguru Raja - Brookline Capital Markets Operator Greetings, and welcome to the Vaxart's Second Quarter 2022 Business Update and Financial Results Conference Call. [Operator Instructions].

Vaxart, Inc. Press Releases

Vaxart announces highly regarded biotech executive elaine j. heron, ph. d.

Dr. heron brings DEC ades of experience in executive leadership and life sciences research and development to vaxart' s board dr. heron brings DEC ades of experience in executive leadership and life sciences research and development to vaxart' s board